Clinical trials: Type 1 or 2 Diabetes
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 1 or 2 Diabetes
This trial is conducted in Asia. The aim of this trial is to investigate the efficacy of biphasic insulin aspart 30 on postprandial glycaemic control.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- NCT00617565
- Testing
- biphasic insulin aspart, biphasic human insulin
- Where
- 6 sites in China
- Volunteers
- 219 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1 or 2
Safety and Efficacy of the GlucoMe APP in Patients With Uncontrolled Diabetes Treated With MDI
The study will evaluate the safety and efficacy of computerized GlucoMe App in patients with uncontrolled diabetes treated with MDI.
- Trial name
- NCT03017287
- Testing
- GlucoMe App
- Where
- Israel
- Volunteers
- 40 people
- Sponsor
- GlucoMe
Type 2 Diabetes Mellitus
Effects of Exenatide Long-Acting Release on Glucose Control and Safety in Subjects With Type 2 Diabetes Mellitus(DURATION - 1)
A Randomized, Open-Label, Multicenter, Comparator-Controlled Study to Examine the Effects of Exenatide Long-Acting Release (LAR) on Glucose Control (HbA1c) and Safety in Subjects with Type 2 Diabetes Mellitus Managed with Diet…
- Trial name
- NCT00308139
- Testing
- exenatide, long acting release, exenatide
- Where
- 25 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Trial Comparing the Efficacy and Safety of HR17031 Injection to INS068 Injection and to SHR20004 Injection in Patients With Type 2 Diabetes
The aim of this trial is to compare the efficacy and safety of HR17031 versus INS068 and SHR20004 in subjects with type 2 diabetes.
- Trial name
- NCT05333835
- Testing
- HR17031 injection, INS068 injection, SHR20004 injection
- Where
- China
- Volunteers
- 455 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Treatment Use of Generex Oral-lyn™ in Patients With Diabetes
The objective of this Treatment IND protocol is to provide Generex Oral-lyn™ to patients with serious or life-threatening Type 1 or Type 2 diabetes mellitus, with no satisfactory alternative therapy available for treatment of…
- Trial name
- NCT00948493
- Testing
- Buccal insulin spray
- Sponsor
- Generex Biotechnology Corp.
Diabetes, Diabetes Mellitus, Type 2
Comparison of NN5401 With Biphasic Insulin Aspart 30 in Type 2 Diabetes
This trial is conducted in Asia, Europe and Oceania. The aim of this clinical trial is to compare NN5401 (insulin degludec/insulin aspart) with biphasic insulin aspart 30 in subjects with type 2 diabetes.
- Trial name
- BOOST™ (NCT01009580)
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart 30
- Where
- 53 sites in Australia, Denmark and 8 more
- Volunteers
- 447 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Safety of Levemir® in Diabetes
This observational study is conducted in North America. The aim of this observational study is to evaluate the incidence of adverse events while using Levemir® under normal clinical practice conditions.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PREDICTIVE™ (NCT00706017)
- Testing
- insulin detemir
- Where
- Mexico
- Volunteers
- 2,282 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Comparison of Glycemic Control in Obese Diabetics Using Three Different Pen Needles
Anxiety about needles is a concern commonly expressed by diabetics when beginning insulin therapy. A shorter, thinner pen needle that delivers insulin with the safety and efficacy profile of longer pen needles may appeal to many…
- Trial name
- NCT01231984
- Testing
- 4 mm x 32G Pen Needle, 8mm x 31G Pen Needle, 12.7mm x 29G Pen Needle
- Where
- 10 sites in United States
- Volunteers
- 293 people
- Sponsor
- Becton, Dickinson and Company
Diabetes, Diabetes Mellitus, Type 1
Safety of Insulin Detemir for the Treatment of Insulin Dependent Type 1 or Type 2 Diabetes Mellitus
This trial is conducted in North America. The aim of this trial is to evaluate the safety of insulin detemir for the treatment of diabetes.
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PREDICTIVE™ (NCT01709929)
- Testing
- insulin detemir
- Where
- Canada
- Volunteers
- 2,287 people
- Sponsor
- Novo Nordisk A/S
Pain, Diabetic Neuropathies
A Research Study of V3381 for the Treatment of Diabetic Peripheral Neuropathic Pain
The objective of this study is to investigate the safety and efficacy of an investigational drug, V3381, for the treatment of diabetic peripheral neuropathic (DPN) pain (pain in one's feet and legs, or even in one's hands and…
- Trial name
- NCT00375960
- Testing
- V3381
- Where
- 6 sites in United States, Canada
- Volunteers
- 50 people
- Sponsor
- Vernalis (R&D) Ltd
Diabetes, Diabetes Mellitus, Type 1
Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics
This trial is conducted in the United States of America (USA). The aim of this clinical trial is to assess and compare the effect on blood sugar control of insulin detemir and insulin aspart or insulin detemir alone administered…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
- Trial name
- NCT00773279
- Testing
- FlexTouch®, FlexPen®
- Where
- 65 sites in United States
- Volunteers
- 242 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Comparing Insulin Degludec/Liraglutide and Insulin Degludec in Combination With Metformin in Chinese Subjects With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Therapy and Metformin With or Without One Other Oral Antidiabetic Drug (OAD)
This trial is conducted in Asia. The aim of this trial is to confirm the superiority of insulin degludec/liraglutide versus insulin degludec in controlling glycaemia in Chinese subjects with type 2 diabetes mellitus after 26…
- Trial name
- DUAL™ II China (NCT03175120)
- Testing
- Insulin degludec/liraglutide, Insulin degludec
- Where
- 37 sites in China, Hong Kong
- Volunteers
- 453 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers
This is a an open-label, randomized, single dose, four-way crossover, multi-stage study enrolling 20 healthy adult male and female subjects per part.
- Trial name
- NCT01725672
- Testing
- Metformin, 500 mg extended release tablet, Metformin, 1000 mg extended release tablet, Glimepiride, 1 mg immediate release tablet
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Diabetes, Type 1, Diabetes, Type 2
Safety of Inhaled Insulin With Type 1 and Type 2 Diabetes
Pulmonary Safety in Diabetics with T/I
- Trial name
- NCT00308737
- Testing
- Technosphere® Insulin Inhalation Powder, Usual Care
- Where
- 176 sites in United States, Canada and 6 more
- Volunteers
- 2,053 people, healthy volunteers welcome
- Sponsor
- Mannkind Corporation
Advanced Solid Tumor, Metastatic Solid Tumor
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-102 as a single agent and in combination with conventional anti-cancer drugs, pembrolizumab or trastuzumab…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT05824975
- Testing
- GI-102 subcutaneous (SC), GI-102, doxorubicin
- Where
- 11 sites in United States, South Korea
- Volunteers
- 358 people
- Sponsor
- GI Innovation, Inc.
Diabetes (Insulin-requiring, Type 1 or Type 2), Pancreatogenic Diabetes Mellitus
DIA:CONN P8(Smart Insulin Pen) Study in Diabetes Patients
A Multicenter, Open label, Randomized, Comparative Study to Evaluate the Efficacy and Safety of Electric Smart Insulin Pen DIA:CONN P8 in patients with Type 1, Type 2 or Pancreatogenic Diabetes Mellitus under Multiple Dose…
- Trial name
- NCT06406439
- Testing
- Smart Insulin Pen, Injection of bolus insulin via conventional therapy using insulin pen
- Where
- 9 sites in South Korea
- Volunteers
- 120 people
- Sponsor
- G2e Co., Ltd
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes
This study looks at overall impact of the use of DuraTouch® in terms of ease, convenience to use and satisfaction in participants with either type 1 or type 2 diabetes.The study will last for about 12 weeks.
- Trial name
- NCT07052292
- Testing
- DuraTouch®
- Where
- 11 sites in Poland
- Volunteers
- 128 people
- Sponsor
- Novo Nordisk A/S
Healthy Subjects, Obesity
Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes
The phase 1 portion of the study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TLC-6740 after single- and multiple-ascending doses in healthy subjects.
- Conditions
- Healthy Subjects, Obesity, Type 2 Diabetes
- Trial name
- NCT05822544
- Testing
- TLC-6740 Oral Solution, TLC-6740 Tablet, Drug Metabolizing Enzyme
- Where
- 4 sites in New Zealand
- Volunteers
- 564 people, healthy volunteers welcome
- Sponsor
- OrsoBio, Inc
Type 1 Diabetes, Type 2 Diabetes
A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes
The purpose of this study is to investigate the user experience of an integrated insulin management system (IIM) in participants with type 1 or type 2 diabetes.
- Trial name
- NCT04484779
- Testing
- IIM System, Insulin Lispro and/or Insulin Glargine
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Eli Lilly and Company
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW III Asia Registry Orsiro Stent System
Cliflical evaluation of th' Orsiro LESS 10 diabetic subjects requiring coronary revasculariza t ion with Drug Eluting Stefl ts (DES) .880 subjects will be enrolled in this registry.
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01941290
- Where
- 19 sites in China, India and 3 more
- Volunteers
- 387 people
- Sponsor
- BIOTRONIK Asia Pacific Pte Ltd